Last 43 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -42.43 | 19087.50 | 22.12 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 12.44 | 4.99 | 3.22 | 3.60 | 5.02 | 6.31 | 8.14 | 14.25 | 15.59 | 32.81 | 212.74 | — | — | — | — | — | — | — | — | — | — |
| — | -21.0% | -60.5% | -74.7% | -67.8% | -80.8% | -96.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 27.88 | 15.74 | 9.67 | 10.21 | 13.72 | 16.92 | 19.23 | 19.76 | 13.83 | 8.36 | 8.89 | — | — | — | — | 7.27 | 6.05 | 5.80 | 3.31 | 3.87 | 2.40 |
| — | -7.0% | -49.7% | -48.3% | -0.8% | +102.5% | +116.3% | — | — | — | — | — | — | — | — | +87.9% | +152.1% | +238.5% | +6.7% | -61.9% | — | |
| P/FCF | — | 16.63 | 17.52 | — | 32.17 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 123.20 | 20.50 | — | — | 436.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -71.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 152.29 | 23.06 | — | — | 1092.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -86.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.0% | 103.9% | 90.7% | 89.4% | 90.5% | 87.7% | 93.3% | 94.4% | 96.4% | 98.3% | 97.6% | — | — | — | — | — | — | — | — | — | — |
| — | +18.4% | -2.8% | -5.3% | -6.2% | -10.8% | -4.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -25.1% | 2.5% | 13.0% | -5.7% | -6.5% | -0.7% | -30.7% | -95.8% | -128.0% | -500.6% | -3311.6% | — | — | — | — | — | — | — | — | — | — |
| — | +482.5% | +142.5% | +94.0% | +94.9% | +99.9% | +99.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -28.9% | 0.0% | 14.2% | -9.4% | -10.0% | -5.2% | -33.3% | -100.6% | -148.0% | -517.2% | -4307.0% | — | — | — | — | — | — | — | — | — | — |
| — | +100.5% | +142.6% | +90.7% | +93.2% | +99.0% | +99.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -60.4% | 0.0% | 11.7% | -6.7% | -6.8% | -3.6% | -18.6% | -32.9% | -29.1% | -28.6% | -122.7% | — | — | — | -244.5% | -39.6% | -25.2% | -20.2% | -15.3% | -9.0% | -6.8% |
| — | +100.6% | +163.1% | +79.8% | +76.7% | +87.4% | +84.8% | — | — | — | +49.8% | — | — | — | -1494.3% | -339.9% | -272.1% | -204.9% | -153.2% | +85.1% | — | |
| ROA | -29.7% | 0.0% | 5.4% | -3.0% | -3.1% | -1.7% | -8.5% | -16.4% | -15.7% | -18.0% | -37.7% | -17.9% | -15.7% | -13.3% | -33.5% | -11.3% | -8.7% | -8.0% | -6.8% | -4.4% | -3.5% |
| — | +100.6% | +164.1% | +82.0% | +80.0% | +90.7% | +77.5% | +7.9% | +0.2% | -35.3% | -12.7% | -58.2% | -79.9% | -64.8% | -391.9% | -153.7% | -147.2% | -130.1% | -160.5% | -823.3% | -97.9% | |
| ROIC | -76.3% | 3.4% | 26.3% | -10.1% | -6.8% | -0.5% | -21.6% | -37.5% | -21.6% | -23.0% | -49.9% | -61.1% | -34.5% | -17.7% | -18.1% | -13.8% | -9.7% | -10.1% | -7.9% | -5.0% | -4.9% |
| — | +732.4% | +222.0% | +73.2% | +68.3% | +97.7% | +56.8% | +38.6% | +37.3% | -29.9% | -175.9% | -343.8% | -255.0% | -75.1% | -128.9% | -172.8% | -98.9% | -104.7% | -238.1% | -48.3% | +24.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.38 | 0.03 | 0.04 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.50 | 0.15 | — | — | — | — | 2.63 | 1.85 | 1.46 | 1.21 | 1.05 | 0.80 |
| — | +1363.8% | -2.9% | +27.5% | -22.8% | -94.8% | -80.0% | — | — | — | — | — | — | — | — | +149.7% | +130.4% | +93.2% | +72.8% | -73.2% | — | |
| Debt / EBITDA | — | 12.25 | 0.27 | — | — | 2.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +346.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.75 | 2.76 | 2.79 | 2.73 | 2.75 | 2.97 | 2.82 | 2.85 | 3.64 | 3.19 | 3.32 | 1.38 | 1.81 | 2.73 | 2.72 | 3.65 | 9.17 | 11.70 | 14.17 | 26.57 | 17.44 |
| — | -7.3% | -1.1% | -3.9% | -24.5% | -6.7% | -15.2% | +106.3% | +101.5% | +16.8% | +22.2% | -62.2% | -80.3% | -76.7% | -80.8% | -86.3% | -47.4% | -4.4% | +38.2% | +556.0% | +661.7% | |
| Quick Ratio | 2.33 | 2.37 | 2.38 | 2.33 | 2.33 | 2.60 | 2.52 | 2.60 | 3.36 | 3.09 | 3.30 | 1.38 | 1.81 | 2.73 | 2.72 | 3.65 | 9.17 | 11.70 | 14.17 | 26.57 | 17.44 |
| — | -8.6% | -5.7% | -10.1% | -30.6% | -15.9% | -23.5% | +88.2% | +85.9% | +13.3% | +21.2% | -62.2% | -80.3% | -76.7% | -80.8% | -86.3% | -47.4% | -4.4% | +38.2% | +574.1% | +696.2% | |
| Interest Coverage | -3.91 | 0.80 | 3.77 | -1.34 | -1.22 | -0.12 | -4.69 | -10.04 | -10.58 | -17.75 | -21.59 | -8.68 | -7.13 | -4.78 | -7.51 | -14.19 | -5.57 | -13.30 | -11.37 | -7.71 | -4.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 43 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AVDL stock.
Avadel Pharmaceuticals plc's current P/E is -42.4x. The average P/E over the last 2 quarters is 9554.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Avadel Pharmaceuticals plc's current operating margin is -25.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Avadel Pharmaceuticals plc's business trajectory between earnings reports.